Skip to main content
OpenTrials

Clinical trial condition

TDP-43 Proteinopathies

Explore clinical trials studying TDP-43 Proteinopathies. Study availability and eligibility vary by location and protocol.

870 public trials 211 recruiting studies
Refine in advanced search Browse all conditions

TDP-43 Proteinopathies trial results

Completed

Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00748501

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Metabolic Diseases, +8 more
Locations
  • Coordinated Clinical Research La Jolla, California, United States
  • University of California, Irvine; MDA ALS and Neuromuscular Center, Orange, California, United States
  • California Pacific Medical Center (CPMC), The Forbes Norris MDA/ALS Research Center San Francisco, California, United States
  • The University of Kansas Medical Center (KU) Kansas City, Kansas, United States
View Trial Details
Completed

Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00403104

Conditions
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Central Nervous System Diseases, +9 more
Locations
  • L. Boltzmann Forschungsinstitut, Neurologische Abteilung, Kaiser Franz Josef Hospital, Wien Vienna, Austria
  • UCL Saint-Luc Brussels, Belgium
  • UZ Leuven Leuven, Belgium
  • Hopital Roger Salengro - Clinique Neurologique, Neurologie A Lille, France
View all 26 locations
View Trial Details
Completed

A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

NCT00694941

Conditions
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Central Nervous System Diseases, +9 more
Locations
  • Prof. Maloteaux, UCL Saint-Luc Brussels, Belgium
  • Prof. Wim Robberecht, UZ Leuven Leuven, Belgium
  • Prof. Alain Destee, Hopital Roger Salengro - Clinique Neurologique, Neurologie A Lille, France
  • Prof. Philippe Couratier, Hopital Duruytren Limoges, France
View all 25 locations
View Trial Details
Completed

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

NCT01041222

Conditions
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases, Familial Amyotrophic Lateral Sclerosis, +9 more
Locations
  • Johns Hopkins University Baltimore, Maryland, United States
  • Massachusetts General Hospital-East, Neurology Clinical Trials Unit Charlestown, Massachusetts, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Methodist Neurological Institute Houston, Texas, United States
View Trial Details

Related conditions